Application of polygonum multiflorum hormone in preparation of composition for promoting animal growth hormone secretion

Phyghrelin purified from Polygonum multiflorum activates the ghrelin receptor, and solves the problems of poor stimulation of growth hormone secretion and side effects in the prior art, and achieves safe and effective growth hormone secretion stimulation, which is used to treat aging-related diseases and promote animals. Grow.

CN118892489APending Publication Date: 2024-11-05ZHEN WANG BIOTECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310497763.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-05
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

In the treatment of aging-related diseases, direct injection of growth hormone can easily cause side effects, and the synthetic ghretin receptor agonist also has side effects, which fail to effectively stimulate the frequency of growth hormone secretion, and there is a lack of suitable ghretin on the market. Receptor agonist.

Method used

Edhatin methyl ether-8-O-(6'-O-malonyl)-glucoside was purified from Polygonum multiflorum, named Phyghrelin, which stimulates growth hormone secretion by activating ghrelin receptors, and is prepared to promote the use of promoting Animal growth hormone secretion composition.

Benefits of technology

Phyghrelin safely and effectively stimulates growth hormone secretion by activating ghrelin receptors, reducing the occurrence of side effects, provides a potential treatment for preventing and treating aging-related diseases caused by reduced growth hormone secretion, and is used to promote Animal growth.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118892489A_ABST
    Figure CN118892489A_ABST
Patent Text Reader

Abstract

The invention discloses application of polygonum multiflorum hormone to preparation of a composition for promoting animal growth hormone secretion. The radix polygoni multiflori hormone is emodin monomethyl ether-8-O-(6 '-O-malonyl)-glucoside purified from radix polygoni multiflori and is named as the radix polygoni multiflori hormone Phyghrelin, and the radix polygoni multiflori hormone Phyghrelin is prepared into a composition for promoting secretion of growth hormone of animals.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a physcion methyl ether-8-O-(6'-O-malonyl)-glucoside purified from Polygonum multiflorum, named as Polygonum multiflorum hormone Phyghrelin, and also relates to the use of the Polygonum multiflorum hormone Phyghrelin in preparing a composition for promoting the secretion of animal growth hormone. The present invention belongs to the field of biotechnology. Background Art

[0002] The secretion of animal growth hormone is related to age. For example, the secretion of human growth hormone gradually decreases with age. The decrease in growth hormone secretion is generally believed to be closely related to animal cell metabolism and the occurrence of diseases. The causes and mechanisms of the decrease in growth hormone secretion are not fully understood. Therefore, medical strategies to stimulate growth hormone secretion to treat aging-related diseases are still under research and development testing.

[0003] Ghrelin is a 28-amino acid polypeptide hormone that is mainly secreted by X / A-like cells at the base of the stomach. The third amino acid, serine, is acylated (n-octanoylated modification), and this post-translational modification is considered to be the main reason for ghrelin's biological activity. Ghrelin has been identified as a G protein-coupled receptor (GPCR), which is mainly distributed in the hypothalamus and pituitary gland. After the growth hormone secretion receptor is activated by ghrelin, it mainly increases appetite through the hypothalamus and stimulates the anterior pituitary gland to release growth hormone. In addition, ghrelin also has a regulatory function on metabolism, energy balance and gastrointestinal function in the body. Many studies have pointed out that in aging humans and animal models, the administration of ghrelin and its oral synthetic derivatives has been found to stimulate appetite, increase the pulse of growth hormone secretion, reduce adipose tissue and increase bone turnover rate. In addition, ghrelin agonists have also been found to have the ability to improve cardiovascular disease and learning cognition.

[0004] Current medical research believes that many side effects caused by direct injection of growth hormone (such as edema, joint pain, carpal tunnel syndrome and insulin resistance) are likely caused by directly changing the frequency of growth hormone secretion in the human body; however, clinical studies have shown that activating ghrelin receptors will only stimulate the pulse of growth hormone secretion and will not change the frequency of its secretion, and the occurrence of side effects is also much milder. Therefore, treating aging-related diseases through the mechanism of ghrelin receptor activation is currently considered to be a very promising treatment model. According to literature reports, the current synthetic oral ghrelin receptor agonist still has the risk of causing mild edema, muscle pain, increased blood sugar, vomiting and diarrhea, and there is no ghrelin receptor agonist suitable for clinical treatment on the market.

[0005] Polygonum multiflorum is the root of Polygonum multiflorum, a plant of the Polygonaceae family, and is a common Chinese herbal medicine for anti-aging. Many studies have also found that extracts of Polygonum multiflorum can improve aging-related diseases such as hypercholesterolemia, cardiovascular diseases, and cognitive impairment. These therapeutic effects are very similar to the anti-aging effects produced by ghrelin stimulating the secretion of growth hormone. Therefore, the present invention first speculates that the anti-aging and longevity effects of raw Polygonum multiflorum are likely to be regulated by the pathway of activating ghrelin receptors. Summary of the invention

[0006] Based on the above problems and findings, the present invention uses liquid chromatography-mass spectrometry (LC-MS) to analyze and identify the components contained in raw Polygonum multiflorum ( Figure 1 ), and compared the mass spectrometry analysis results of other literature to confirm the identity of each compound. Among them, compound No. 8 is the special component of raw Polygonum multiflorum, physcion methyl ether-8-O-(6'-O-malonyl)-glucoside, which is named "Phyghrelin" in the present invention. The inventor believes that this unique compound is likely to be the main active ingredient of raw Polygonum multiflorum for anti-aging.

[0007] Therefore, the main purpose of the present invention is to provide a use of Polygonum multiflorum hormone in preparing a composition for promoting the secretion of animal growth hormone.

[0008] The Polygonum multiflorum hormone is purified from Physcion methyl ether-8-O-(6'-O-malonyl)-glucoside of Polygonum multiflorum and named as Polygonum multiflorum hormone Phyghrelin. The Polygonum multiflorum hormone Phyghrelin is prepared into a composition for promoting the secretion of growth hormone in animals.

[0009] Preferably, the composition is an animal medicine composition for stimulating the secretion of growth hormone in animals.

[0010] Preferably, the animal pharmaceutical composition is a pharmaceutical composition for human anti-aging.

[0011] Preferably, the pharmaceutical composition is used for preventing and / or treating aging-related diseases caused by decreased secretion of growth hormone.

[0012] Among them, preferably, the composition is an animal food composition for increasing the secretion of animal growth hormone.

[0013] Among them, preferably, the animal food composition is an animal feed composition.

[0014] Preferably, the animal feed composition is used to help the growth of farmed animals. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 To analyze and identify the components contained in raw Polygonum multiflorum by using liquid chromatography-mass spectrometry (LC-MS).

[0016] Figure 2 To show the different concentrations of Phyghrelin (10 -7 ~10 -4 M) was treated with the drug for 24 hours ( Figure 2 A), and 48 hours ( Figure 2 B) had no significant effect on the cell survival rate.

[0017] Figure 3 This study is to analyze the stimulatory activity of Phyghrelin and ghrelin receptor agonist derivatives (GHRP-6) on growth hormone secretion.

[0018] Figure 4 To show that ghrelin receptor antagonists ([D-Arg 1 , D-Phe 5 , D-Trp 7,9 ,Leu 11 ]-substrate P, 0.5μM) inhibits the activity of GHRP-6 and Phyghrelin in stimulating growth hormone secretion. DETAILED DESCRIPTION

[0019] In order to achieve the above-mentioned purpose, the present invention specifically lists the preferred embodiments and describes them in detail with the accompanying drawings as follows:

[0020] Analysis and identification of components in raw Polygonum multiflorum

[0021] Liquid chromatography-mass spectrometry (LC-MS) was used to analyze and identify the components contained in raw Polygonum multiflorum ( Figure 1), and compared the mass spectrometry results of other literature to confirm the identity of each compound (Table 1). Raw Polygonum multiflorum medicinal materials were collected from Benz Agricultural Biotechnology Co., Ltd. and were one to two years old. 51.2g of medicinal materials were crushed by a grinder, added with 500mL of methanol, and extracted by ultrasonic wave at room temperature for 2 hours, and then filtered by vacuum filtration to remove the residue. This extraction process was repeated twice; the two Polygonum multiflorum methanol extracts were combined and filtered through a 0.22μm filter membrane to obtain the sample solution to be tested. For the preparation of the standard solution, take an appropriate amount of THSG and emodin (purity>98%), add 1mL of methanol to dissolve each, and filter with a 0.22μm filter membrane to obtain the standard solution.

[0022] The methanol extract of raw Polygonum multiflorum and the standard solution were analyzed by high performance liquid chromatography (HPLC). The chromatography column was Syncronis C18 column (4.6×250mm, 5μm), the injection volume was 20μL, the flow rate was 1mL / min, and the detection wavelength was 280nm. The mobile phase A was pure water and B was acetonitrile, both containing 0.5% acetic acid. The separation conditions were 0-45min, 10to35%B; 45-65min, 35to 100%B; 65-80min, 100%B for gradient elution.

[0023] The liquid chromatography tandem mass spectrometer used in this experiment was a Surveyor LC system with an automatic sample injection device connected to a linear ion trap mass spectrometer (LTQ mass spectrometer) and equipped with a 5μL sample circle; the liquid chromatography conditions were the same as the above-mentioned HPLC analysis conditions; the ion source adopted electrospray ionization (ESI) positive and negative ion modes, the sheath gas, auxiliary gas and sweep gas used in the ion source were all nitrogen, the spray voltage was 4.5kV, the capillary temperature was heated to 300℃, and the full scan range was m / z 150-1500; the mass analyzer was a linear ion trap mass analyzer, the collision gas used in the linear ion trap was helium, the relative collision energy was 27%, and the parent ion isolation range was 2Da.

[0024] Table 1

[0025]

[0026] Peak 8 compound is the special ingredient Phyghrelin-8-O-(6'-O-malonyl)-glucoside contained in raw Polygonum multiflorum. The present invention named it "Phyghrelin", and believed that this unique compound is likely to be the main active ingredient of raw Polygonum multiflorum for anti-aging. Therefore, this compound was purified from raw Polygonum multiflorum for related activity tests.

[0027] Purification of "Phyghrelin"

[0028] After the methanol extract of Polygonum multiflorum was concentrated under reduced pressure and freeze-dried, 4 g of the extract was weighed, dissolved in 450 mL of pure water and loaded into a separatory funnel. The liquid distribution extraction method was used to extract three times with dichloromethane, ethyl acetate and n-butanol in a ratio of 1:1 to obtain extracts of different polarities. Then, the n-butanol extract was taken and further purified by HPLC to obtain Phyghrelin. The chromatography column was Syncronis C18 column (4.6×250 mm, 5 μm), the flow rate was 1 mL / min, and the detection wavelength was 280 nm; the mobile phase A was pure water and B was acetonitrile, both containing 0.5% acetic acid. The separation conditions were 0-10 min, 18 to 33% B; 10-15 min, 33% B; 15-35 min, from 33 to 55% B for gradient elution, and a total of 2.493 mg of the compound was obtained for subsequent cell experiments.

[0029] Analysis of cytotoxicity of "Phyghrelin"

[0030] First, the cytotoxicity of Phyghrelin was tested using rat pituitary tumor cell line (RC-4B / C cells), and the cell survival rate was analyzed using alamarblue reagent. Rat pituitary tumor cell line RC-4B / C (ATCC number: CRL-1903) was cultured at 1×10 5 The cells / well were cultured in a 24-well plate. The culture medium consisted of 1:1 DMEM and α-MEM, 0.01 mM non-essential amino acids, 15 mM HEPES, 0.2 mg / ml bovine serum albumin (BSA), 2.5 ng / ml epidermal growth factor (EGF), and 10% fetal bovine serum (FBS). After 24 hours of culture, the culture medium was replaced with a medium containing Phyghrelin (10 -7 ~10 -4The culture medium was placed in a cell culture incubator (37°C, 5% CO2) for 24 and 48 hours respectively, and then replaced with a culture medium containing 10% alamarblue in a cell culture incubator for 3 hours. The fluorescence value was detected by a spectrometer (excitation light and scattered light were 560 and 590 nm respectively), and then converted to the cell survival rate; cell survival rate (%) = (absorbance value of the drug-added group / absorbance value of the control group) × 100%. The results showed that different concentrations of Phyghrelin (10 -7 ~10 -4 M) After 24 and 48 hours of drug treatment, there was no significant effect on cell survival rate, see Figure 2 .

[0031] Growth hormone secretion stimulating activity of "Phyghrelin"

[0032] Phyghrelin was used to stimulate the secretion of growth hormone using primary cultured cells of the anterior pituitary gland of rats. The secretion of growth hormone was determined by enzyme-linked immunosorbent assay (ELISA). Sprague Dawley male rats weighing 250-300 g were used. After the rats were anesthetized by intraperitoneal injection of Zoletil 50 (40 mg / kg), the anterior pituitary tissue of the rats was removed and minced. The tissue was broken into single cell forms using three different enzymes: 0.25% (w / v) collagenase type 1a, trypsin, and DNase I. Finally, the cells were filtered through a 100 μm cell strainer at a cell density of 4×10 4 The cells were cultured in a 96-well plate. After two days of culture in a cell culture incubator (37°C, 5% CO2), the original culture medium was replaced with serum-free culture medium and allowed to stand in the incubator for 90 minutes. Finally, the culture medium was replaced with culture medium containing Phyghrelin (10 -7 ~10 -4 M) and GHRP-6 (GHSR agonist, 10 -7 M) culture medium, and the cell culture medium was collected 15 and 30 minutes after drug treatment; the ghrelin receptor antagonist was tested using [D-Arg 1 ,D-Phe 5 ,D-Trp 7,9 ,Leu 11 ]-substance P (GHSRantagonist, 0.5μM), the drug test group contained GHSR antagonist (0.5μM), GHRP-6 (10 -7M), GHRP-6 (10 -7 M)+GHSR antagonist(0.5μM), Phyghrelin(10 -4 M) and Phyghrelin (10 -4 M)+GHSR antagonist (0.5μM) culture medium were treated respectively, and the cell culture fluid was collected 15 minutes after drug treatment. The content of growth hormone secretion in the culture fluid of each group was determined by Rat growth hormone enzyme-linked immunosorbent assay (ELISA) kit.

[0033] Depend on Figure 3 The results showed that Phyghrelin and the derivative of ghrelin receptor agonist (GHRP-6) also showed a significant increase in growth hormone secretion 15 and 30 minutes after treatment, and Phyghrelin (10 -7 ~10 -4 M) stimulates the increase in growth hormone secretion in a drug concentration-dependent manner.

[0034] In addition, ghrelin receptor antagonists ([D-Arg 1 ,D-Phe 5 ,D-Trp 7,9 ,Leu 11 ]-substrate P, 0.5μM) can also inhibit the activity of GHRP-6 and Phyghrelin in stimulating growth hormone secretion ( Figure 4 ). This shows that Phyghrelin of the present invention indeed stimulates the secretion of growth hormone by activating ghrelin receptors.

[0035] Based on the above results, it is shown that Phyghrelin of the present invention can further stimulate the increase of growth hormone secretion by activating ghrelin receptors as a ghrelin receptor agonist.

[0036] Therefore, the present invention first utilizes the Chinese medicine Polygonum multiflorum to purify and identify a natural, safe compound with ghrelin receptor agonist activity, physcion-8-O-(6'-O-malonyl)-glucoside, named "Polygonum multiflorum hormone Phyghrelin", and proves that it has the promoting effect of stimulating the increase of growth hormone secretion, and then applies it to the preparation of a composition for animal medicine and food, or a composition for preventing / treating aging-related diseases caused by decreased growth hormone secretion in the elderly population, or a feed composition for helping animals, such as livestock or aquatic breeding, grow.

[0037] The above description is only illustrative rather than restrictive of the present invention. Those skilled in the art will understand that many modifications, changes or equivalents may be made without departing from the spirit and scope of the present invention as defined in the specification and claims, but all of them will fall within the scope of protection of the present invention.

Claims

1. A use of Polygonum multiflorum hormone in preparing a composition for promoting the secretion of animal growth hormone, characterized in that: The Polygonum multiflorum hormone is purified from Physcion methyl ether-8-O-(6'-O-malonyl)-glucoside of Polygonum multiflorum and named as Polygonum multiflorum hormone Phyghrelin. The Polygonum multiflorum hormone Phyghrelin is prepared into a composition for promoting the secretion of growth hormone in animals.

2. The use according to claim 1, characterized in that The composition is an animal medicine composition, which is used for stimulating the secretion of animal growth hormone.

3. The use according to claim 2, characterized in that The animal medicine composition is a medicine composition for human anti-aging.

4. The use according to claim 3, characterized in that The pharmaceutical composition is used for preventing and / or treating aging-related diseases caused by decreased secretion of growth hormone.

5. The use according to claim 1, characterized in that The composition is an animal food composition, which is used for increasing the secretion of animal growth hormone.

6. The use according to claim 5, characterized in that The animal food composition is an animal feed composition.

7. The use according to claim 6, characterized in that The animal feed composition is used to help the growth of farmed animals.